Rheumatoid arthritis
Conditions
Interventions
1) Shingrix administration to patients who are on methotrexate (MTX) monotherapy
2) Shingrix administration to patients who are on upadacitinib monotherapy (15 mg/day)
3) Shingrix administration to pa
Sponsors
Watanabe Ryu
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients who have given informed consent to participate in this study 2) Patients who are treated with stable dose of 1) methotrexate (MTX) monotherapy, 2) upadacitinib monotherapy (15 mg/day), or 3) MTX + upadacitinib 15 mg/day (combo) for at least 1 months prior to the study entry 3) Patients who are 50 years old or older 4) Patients who can come to our hospital according to the research schedule
Exclusion criteria
Exclusion criteria: 1) Patients on dialysis 2) Pregnant / lactating patients 3) Patients with severe liver damage (Child-Pugh classification C) 4) Patients with serious infections or active tuberculosis 5) Patients with neutropenia ( 10 mg 12) Patients who had a history of using JAK inhibitors and discontinued due to insufficient efficacy 13) Patients who are judged to be inappropriate for participation in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Immunogenicity 4 weeks after 2nd dose of shingrix injection | — |
Secondary
| Measure | Time frame |
|---|---|
| (1) Relapse of RA 12 weeks after the second administration of Singrix (2) Positive rate of anti-gE antibody at 4 weeks after the first administration of Singrix (3) Antibodies of anti-gE antibody 4 weeks after the first and second administration of Singrix (4) Evaluation of gE-specific CD4 + T cells 4 weeks after the first and second administration of Singrix (5) Evaluation of VZV-specific antibody titer 4 weeks after the first and second administration of Singrix (6) Changes in RA disease activity | — |
Contacts
Public ContactRyu Watanabe
Osaka Metropolitan University Hospital
Outcome results
None listed